Preclinical & Clinical Drug Development Services

Preclinical development services evaluate a drug candidate’s safety, pharmacology, pharmacokinetics, and biological activity before human clinical trials. These studies generate data to support regulatory submissions such as Investigational New Drug (IND) applications.

Preclinical development occurs before human testing and focuses on understanding a drug candidate’s safety and biological effects using laboratory and animal studies. Clinical development evaluates safety and efficacy in human participants through phased clinical trials.

WuXi AppTec supports a broad range of therapeutic modalities, including small molecules, biologics, peptides, oligonucleotides, antibody-drug conjugates (ADCs), vaccines, PROTACs, and other advanced therapeutics.

An integrated approach can improve communication between scientific teams, reduce delays between development stages, enhance data consistency, and help sponsors make informed decisions more efficiently throughout drug development.

By combining discovery biology, DMPK, bioanalysis, toxicology, pathology, and clinical laboratory services within one integrated organization, WuXi AppTec helps reduce operational complexity while delivering high-quality data that support regulatory submissions and development milestones.